Biotech Industry Not Immune To Drug Safety Concerns, Genentech CEO Says

Biogen Idec's and Elan's suspension of Tysabri shows the biotech industry is susceptible to the safety debate, Genentech's Levinson says. The T-cell blocker Raptiva has a different mechanism of action than Tysabri and has a clean safety database, Genentech notes.